Ospemifene, a Selective Estrogen Receptor Modulator, Enhances Oligodendrocyte Myelination and Preserves...

Area of Science:

• Neuroscience
• Pharmacology
• Regenerative Medicine

Background:

• Insufficient myelin regeneration is a key issue in central nervous system (CNS) injuries and diseases like multiple sclerosis (MS).
• Repurposing FDA-approved drugs to promote oligodendrocyte (OL) differentiation offers a viable strategy for myelin repair and functional recovery.

Purpose of the Study:

• To investigate the potential of ospemifene, a selective estrogen receptor modulator (SERM), in promoting myelin repair.
• To evaluate ospemifene's efficacy in preclinical models of CNS injury and demyelination.

Main Methods:

• Assessed ospemifene's effect on oligodendrocyte precursor cell (OPC) differentiation in vitro and in vivo.
• Evaluated ospemifene's protective effects in neonatal mice subjected to hypoxia.
• Tested ospemifene in experimental autoimmune encephalomyelitis (EAE) and toxin-induced demyelination mouse models.

Main Results:

• Ospemifene significantly promoted OPC differentiation and myelin sheath formation.
• In hypoxic mice, ospemifene prevented myelin deficits and preserved neurofunction.
• Ospemifene treatment improved functional outcomes and enhanced myelin regeneration in EAE and demyelination models.

Conclusions:

• Ospemifene demonstrates significant promyelination effects across various preclinical models.
• Ospemifene is a promising therapeutic candidate for treating demyelinating diseases.